Participation in phase 1 trials for patients with cancer

[...]the treatment-related death risk always remained below 1% in all periods and across all cancers, except pancreatic cancer. [...]the sample size of CTEP-sponsored phase 1 studies was usually lower than those of industry-sponsored studies, increasing the risk of bias due to sparse data. Because s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) Jg. 400; H. 10351; S. 473 - 475
1. Verfasser:	Italiano, Antoine
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Elsevier Ltd 13.08.2022 Elsevier Limited
Schlagworte:	Cancer Cancer therapies Clinical trials Clinical Trials, Phase I as Topic Cytotoxicity Drugs FDA approval Hematology Human subjects Humans Medical research Neoplasms - therapy Oncology Pancreatic cancer Participation Patient Participation Patients Pharmaceutical industry Response rates Tumors United States > US
ISSN:	0140-6736, 1474-547X, 1474-547X
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!